Developer of yeast-based therapeutic human antibodies designed to improve the quality of the therapeutic lead.
Developer of yeast-based therapeutic human antibodies designed to improve the quality of the therapeutic lead.
Drug Discovery📍 Lebanon, NHFounded 2007
Current Valuation
$1.1B
as of 2015-Q1
UNICORN
QL Price
$1.1B
0% vs last round
QuantLogix's current estimate for Adimab, published 2026-09-27 — in line with the last disclosed round of $1.1B (2015-Q1).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.1B
2015-Q1
weight 0
Secondary market print
$1.1B
2026-06-27
weight 0.58
How this price has held up
No round has priced for Adimab since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Adimab, 2026-09-27 (63a508a706b6ec63).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Adimab going public?
No. Adimab is private and has not filed to go public. There is no S-1 on file.
What is Adimab's valuation in 2026?
Adimab is valued at $1.1B as of 2015-Q1, set by its Later Stage VC ($100M, Jan 2015). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Adimab filed an S-1?
No public S-1 is on file for Adimab.
How much has Adimab raised?
Adimab has raised $142.56M in total, most recently a Later Stage VC of $100M in Jan 2015.
Is Adimab publicly traded — can you buy Adimab stock?
No. Adimab is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Adimab on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2007
HQ
Lebanon, NH
Employees
139
Total Raised
$142.56M
Last Round
Later Stage VC — $100M (Jan 2015)
IPO Status
private
Fundraising Status
Later Stage VC · $100M · 11y 8mo ago
privateTotal raised $142.56M
Secondary Market
Implied price / share
$57
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Later Stage VC
$100M
Jan 2015
—
$1.1B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Adimab — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
10
via careers page
Product-build share
50%
engineering, research, product, design
Trajectory
steady
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Antibody EngineeringProtein and TCR Engineering[Antibody Engineering](https://adimab.com/capabilities/antibody-engineering/)[Protein and TCR Engineering](https://adimab.com/capabilities/protein-engineerinOptional medical FSA, LPFSA, and DCRA accounts availableFamily and community
Counted from Adimab's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
BiotechnologyCollaborationHealth Care
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2015-Q1. Refreshed quarterly.